百草味坚果礼盒重958克，实际坚果仅33克，因命名涉及误导遭网友投诉，客服称将向上级反馈 。 整理 ｜徐子欣 点击上方【36氪随声听】，一键收听大公司热门新闻。听完音频记得添加进入 【我的小程序】 中哟！ 航班管家数据显示，截至1月26日，2026年2月已有49条航线取消全部航班，比一月进一步增加。2026年1月，中国大陆赴日本航班取消率达47.2%，较 2025年12月增长7.8个百分点。1月26日下午，国航、东航、南航陆续发布通知称，1月26日前出票，航班起飞日期在2026年3月29日（含）至2026年10月 24日（含）的日本进出港或经停航班，可免费退改签。在此之前，免费退改签政策执行到3月28日。（第一财经） 肯德基回应外送产品涨价，堂食价格保持不变 1月26日起，肯德基对旗下外送产品价格进行小幅调整，平均调整金额为0.8元，堂食价格维持不变，"疯狂星期四""周末疯狂拼""OK餐三件套"等热门优惠 套餐也保持原价稳定，此举引发市场对快餐行业外送定价策略的关注。 理想汽车内部会曝光：重启人形机器人 腾讯元宝春节派10亿现金，马化腾希望重现当年微信红包盛况 邵氏兄弟拟45亿收购正午阳光 保时捷中国首席执行 ...

今日热点导览 TOP 3 大新闻 百草味客服回应958克坚果礼盒，实际坚果仅占33克 近日，有网友爆料称在网购平台购买的百草味"坚果大礼盒"存在宣传误导问题——礼盒标称重量958 克，实际真正的坚果仅33克，其余多为饮料和饼干类零食，1月25日，记者在百草味官方旗舰店查询发 现，涉事系列礼盒以"坚果大礼盒"为商品名，主图展示腰果、夏威夷果、核桃等坚果，未提及含饮料及 非坚果类成分。仅点开详情小图，才能看到礼盒具体内容。不少网友质疑，礼盒中非坚果成分占比极 高，却以"坚果大礼盒"命名，明显误导消费者。针对此事，百草味官方旗舰店客服回应称，该系列坚果 大礼盒均含有品牌特色饮品，已记录网友质疑并将向上反馈，暂无进一步解决方案。（现代快报） 49条中日航线取消全部航班，免费退改签延长到10月24日 航班管家数据显示，截至1月26日，2026年2月已有49条航线取消全部航班，比一月进一步增加。2026年 1月，中国大陆赴日本航班取消率达47.2%，较2025年12月增长7.8个百分点。1月26日下午，国航、东 航、南航陆续发布通知称，1月26日前出票，航班起飞日期在2026年3月29日（含）至2026年10月24日 （ ...

Group 1: Company Developments - Jia Guolong, founder of Xibei Catering Group, announced a return to frontline operations, focusing on core business rather than personal branding, with an expected cumulative loss exceeding 600 million yuan from September 2025 to March 2026, and plans to close 102 stores, accounting for 30% of total outlets [1] - Ericsson's CEO Börje Ekholm indicated plans to continue layoffs, with approximately 5,000 employees expected to be cut in 2025 and a similar reduction anticipated in 2026 [3] - Merck has ceased acquisition talks with Revolution Medicines, which was valued at around 30 billion yuan, due to disagreements on pricing, although negotiations could potentially resume [6] Group 2: Market Trends and Pricing - KFC has raised delivery prices by an average of 0.8 yuan while keeping dine-in prices unchanged, citing the need to address operational cost changes [5] - The Chinese Ministry of Commerce emphasized the country's commitment to high-level opening-up and innovation in trade, positioning China not only as a global factory but also as a significant market for international products [9] - The service retail sector in China is projected to grow by 5.5% in 2025, with notable growth in cultural, leisure, tourism, and transportation services [10] Group 3: New Product Launches - United Imaging Medical announced the approval of its innovative dual-source CT, uCT SiriuX, by the National Medical Products Administration (NMPA) [7] Group 4: Investment Activities - CVC Capital Partners has agreed to acquire Marathon Asset Management for a total consideration of up to 1.2 billion USD, including 400 million USD in cash and up to 800 million USD in CVC equity [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) due to the recovery of domestic business and continuous breakthroughs in innovative products [5]. Core Views - The company reported a revenue of 6.016 billion yuan for the first half of 2025, representing a year-on-year increase of 12.79%, and a net profit attributable to shareholders of 999.8 million yuan, up 5.03% year-on-year [7]. - The domestic revenue reached 4.873 billion yuan, with a year-on-year growth of 10.74%, while overseas revenue was 1.142 billion yuan, growing by 22.48% year-on-year [7]. - The overall gross margin for the first half of 2025 was 47.93%, a decrease of 2.44 percentage points year-on-year, with service business gross margin remaining above 60% [7]. - The company is expected to achieve revenues of 12.604 billion yuan, 15.157 billion yuan, and 18.224 billion yuan for 2025, 2026, and 2027 respectively, with corresponding year-on-year growth rates of 22.37%, 20.25%, and 20.24% [6][7]. Financial Performance Summary - For 2025, the company is projected to have a net profit attributable to shareholders of 1.871 billion yuan, with a year-on-year growth of 48.26% [6]. - The earnings per share (EPS) for 2025 is estimated at 2.27 yuan, with a projected price-to-earnings (P/E) ratio of 65.57 [6][9]. - The company’s total market capitalization is approximately 122.67 billion yuan, with a closing price of 148.84 yuan [3].

Core Insights - The company reported a revenue of 10.3 billion yuan and a net profit of 1.262 billion yuan for the fiscal year 2024, with a proposed cash dividend of 0.80 yuan per 10 shares [1] - Despite fluctuations in revenue due to domestic equipment update policies, the company achieved significant market performance through innovation and overseas expansion [1][2] - The company's market share for high-end products increased by nearly 5 percentage points, ranking first in the new market share for imaging products in China [3] Financial Performance - For Q1 2025, the company reported a revenue of 2.478 billion yuan and a net profit of 370 million yuan, showing a year-on-year growth of 5.42% and 1.87% respectively [2] - The service revenue for 2024 reached 1.356 billion yuan, a year-on-year increase of 26.80%, contributing 13.16% to total revenue, marking a historical peak [16] Market Position - The company achieved a 22% share of total revenue from overseas business, with a year-on-year growth of over 35% [1][12] - The company’s products are now present in over 85 countries and regions, with more than 14,800 medical and research institutions utilizing its equipment [12] Product Innovation - The company launched several innovative products, including the world's first dual-source wide-body CT and advanced MRI systems, enhancing imaging capabilities significantly [4][5] - The company has developed a vertical innovation system covering core components and systems, achieving a leading position in self-research and development of key technologies [9][10] Strategic Expansion - The company is expanding its presence in North America and Europe, with significant installations in top medical institutions and the establishment of a European headquarters [13][14] - The company is also making strides in emerging markets, with notable growth in Latin America and Africa, and has signed strategic partnerships to enhance its global reach [15] Industry Trends - The regulatory environment is becoming more supportive of high-end medical device innovation, particularly in AI-enabled medical devices, which are projected to grow significantly in the coming years [17] - The company is positioned to leverage its strong innovation capabilities and global strategy to redefine its market presence from "Made in China" to "Intelligent Manufacturing Globally" [17]